Addendum: Systemic AL amyloidosis: current approach and future direction

Maroun Bou Zerdan; Lewis Nasr; Farhan Khalid; Sabine Allam; Youssef Bouferraa; Saba Batool; Muhammad Tayyeb; Shubham Adroja; Mahinbanu Mammadii; Faiz Anwer; Shahzad Raza; Chakra P. Chaulagain

doi:10.18632/oncotarget.28478

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Addendum:

Addendum: Systemic AL amyloidosis: current approach and future direction

PDF | How to cite

Oncotarget. 2023; 14:721-721. https://doi.org/10.18632/oncotarget.28478

Metrics: PDF 734 views | ?

Maroun Bou Zerdan¹, Lewis Nasr², Farhan Khalid³, Sabine Allam⁴, Youssef Bouferraa⁵, Saba Batool⁶, Muhammad Tayyeb⁷, Shubham Adroja⁸, Mahinbanu Mammadii¹, Faiz Anwer⁹, Shahzad Raza⁹ and Chakra P. Chaulagain¹⁰

¹Department of Internal Medicine, SUNY Upstate Medical University, Syracuse, NY 13210, USA
²University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
³Department of Internal Medicine, Monmouth Medical Center, Long Branch, NJ 07740, USA
⁴Department of Medicine and Medical Sciences, University of Balamand, Balamand, Lebanon
⁵Department of Internal Medicine, Cleveland Clinic, Cleveland, OH 44195, USA
⁶Department of Internal Medicine, UnityPoint Methodist, Peoria, IL 61636, USA
⁷Department of Internal Medicine, Monmouth Medical Center, Long Branch, NJ 07740, USA
⁸Hematology and Medical Oncology, Houston Methodist Cancer Center, Houston, TX 77094, USA
⁹Department of Hematology-Oncology, Cleveland Clinic, Cleveland, OH 44195, USA
¹⁰Department of Hematology-Oncology, Myeloma and Amyloidosis Program, Maroone Cancer Center, Cleveland Clinic Florida, Weston, FL 33331, USA

Published: July 20, 2023

Copyright: © 2023 Bou Zerdan et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has an addendum: Research funding was obtained from the Cleveland Clinic Florida, Maroone Cancer Center, Malignant Hematology Research Fund.

Original article: Oncotarget. 2023; 14:384-394. DOI: https://doi.org/10.18632/oncotarget.28415.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28478

Publication Alerts

Post-Publication Promotion

Publication Discount

Addendum:

Addendum: Systemic AL amyloidosis: current approach and future direction